Ticker: CPRX price: 1.89$ 52week low 0.39$ 52week high 2.80$
Average Volume (3 month)3: 322,621 Average Volume (10 day)3: 1,910,870 Shares Outstanding5: 18.04M Float: 12.56M % Held by Insiders1: 30.62% % Held by Institutions1: 14.60% Shares Short (as of 15-Mar-10)3: 21.56K Short Ratio (as of 15-Mar-10)3: 0.1 Short % of Float (as of 15-Mar-10)3: 0.20%
Rodman en Renshaw price target 9$
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPP-109 Clinical Trial Data to be Presented at the American Society of Addiction Medicine Annual Medical-Scientific Conference on April 16to present a Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence. Investigator for the trial and will discuss data from Catalyst's U.S. Phase II trial evaluating CPP-109, Catalyst's form of vigabatrin, to treat cocaine addiction
Developing a Drug to Fight Drug Addiction CPP-109 | Catalyst Pharmaceutical Partners | Fighting drug addiction
catalyst is a specialty pharmaceutical company of Coral Gables, Florida, that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction. Catalyst is developing vigabatrin (designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine and other addictive substances. The National Institute on Drug Abuse has stated that finding a pharmacological treatment for cocaine addiction is their number one research priority. The U.S. Food and Drug Administration has recognized that cocaine addiction is a "serious, life-threatening condition for which there is no current drug treatment," and the National Institute on Drug Abuse (NIDA) has stated that finding a pharmacological treatment for cocaine addiction is their number one research priority. Because of the high social and financial cost of addiction, Catalyst's mission to develop a treatment for drug addiction could prove beneficial not only to addicts, but to investors and to society at large. Previous studies in established animal models of addiction, involving both rats and primates, have shown that vigabatrin interrupts the neural mechanisms essential for addiction. In preclinical studies, vigabatrin prevented the characteristic drug-seeking behavior of addicted animals. Three human trials of vigabatrin have been completed in Mexico with patients addicted to cocaine or methamphetamine, including a U.S. Phase II 103-patient, double-blind, placebo-controlled trial completed in 2007. Data from these three trials provide clinical evidence of vigabatrin's potential as a safe and effective treatment for patients with these addictions
How CPP-109 Works The release of dopamine in the brain causes the "high" or exaggerated sense of pleasure associated with drug abuse. CPP-109 works by indirectly lowering the level of dopamine in the brain. Specifically, GABA — gamma-aminobutyric acid — is a neurotransmitter in the brain that inhibits the release of dopamine. GABA, however, is broken down by GABA transaminase (GABA-T). CPP-109 works by inhibiting GABA-T and consequently increasing the level of GABA, which then lowers the level of dopamine and turns off the "high." CPP-109 works without the apparent side effects typically associated with GABA agonists. Thus targeting brain GABAergic systems with drugs such as CPP-109 is a potentially effective treatment for cocaine, methamphetamine and other substance dependencies.
Market Data 
Markets 
AI
